Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|October 9, 2013
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaMichele Del Vecchio, Lorenza Di Guardo, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2022
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCTGeert Spierenburg, Peter Grimison, Christine Chevreau, et al.
Targeted Oncology|November 10, 2021
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
Tumori|July 7, 2023
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinibMassimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
International Journal of Cancer|October 8, 2008
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patientsPaola Nisticò, Imerio Capone, Belinda Palermo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Cancer Investigation|February 4, 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programPaolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2014
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanomaEster Simeone, Giusy Gentilcore, Diana Giannarelli, et al.
Frontiers in Oncology|March 27, 2020
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II StudyFrancesca Urbani, Virginia Ferraresi, Imerio Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Tumor immune microenvironment-associated prognostic and mifamurtide-response gene signatures for localized osteosarcoma: a correlative study of the ISG/OS2 trialEmanuela Palmerini, Maria Rosaria Sapienza, Stefano A Pileri, et al.
Pageof 12